Evommune (EVMN) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Evommune had return on equity of -54.4% (up from -112.1%), debt-to-equity of 0.01 (down from 0.02), a current ratio of 8.57 (up from 2.64) and return on assets of -33.7% (up from -55.3%). A current ratio of 8.57 means current assets exceed current liabilities.

Evommune Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023
Period ending	Dec 2025	Dec 2024	Dec 2023
Valuation Ratios
P/S Ratio	41.52	-	-
P/B Ratio	2.63	-	-
Price/Tangible Book	2.63	-	-
Enterprise Value Ratios
EV/Revenue	55.49	-	-
Profitability & Returns
Return on Equity (ROE)	-54.42%	-112.09%	-
Return on Assets (ROA)	-33.67%	-55.28%	-
Return on Capital Employed (ROCE)	-39.20%	-145.60%	-50.20%
Leverage & Solvency Ratios
Debt/Equity	0.01	0.02	0.02
Liquidity Ratios
Current Ratio	8.57	2.64	11.67
Quick Ratio	8.33	2.58	11.53
Efficiency Ratios
Asset Turnover	0.09	0.09	-
Yield & Distribution Ratios
Earnings Yield	-12.76%	-	-
FCF Yield	-14.21%	-	-
Buyback Yield	-306.86%	-20.35%	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Evommune Financial Ratios

What is Evommune's return on equity?

Evommune's return on equity (ROE) was -54.4% for fiscal 2025 (period ended Dec 31, 2025). It was -112.1% a year earlier.

What is Evommune's debt-to-equity ratio?

Evommune's debt-to-equity ratio was 0.01 for fiscal 2025 (period ended Dec 31, 2025). It was 0.02 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition